Dimitri E. Grigoriadis

Neurocrine Biosciences (United States) — United States

Neuroscience · Life Sciences

57h-index9.8kcitations166works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Stress Responses and Cortisol(101), Hormonal Regulation and Hypertension(40), Receptor Mechanisms and Signaling(38), Tryptophan and brain disorders(36), Neuroscience and Neuropharmacology Research(32)

Publications165 total

Corticotropin-releasing factor receptors in GtoPdb v.2025.3
IUPHAR/BPS Guide to Pharmacology CITE·2025Open Access
Corticotropin-releasing factor receptors in GtoPdb v.2023.1
IUPHAR/BPS Guide to Pharmacology CITE·2023· 1 citedOpen Access
Pharmacokinetic and Pharmacologic Characterization of the Dihydrotetrabenazine Isomers of Deutetrabenazine and Valbenazine
Clinical Pharmacology in Drug Development·2022· 10 citedOpen Access
Efficacy of Vesicular Monoamine Transporter 2 Inhibition and Synergy with Antipsychotics in Animal Models of Schizophrenia
Journal of Pharmacology and Experimental Therapeutics·2022· 7 citedOpen Access
Effects of NBI-98782, a selective vesicular monoamine transporter 2 (VMAT2) inhibitor, on neurotransmitter efflux and phencyclidine-induced locomotor activity: Relevance to tardive dyskinesia and antipsychotic action
Pharmacology Biochemistry and Behavior·2020· 22 cited
The importance of target binding kinetics for measuring target binding affinity in drug discovery: a case study from a CRF1 receptor antagonist program
Drug Discovery Today·2019· 36 cited
Corticotropin-releasing factor receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database
IUPHAR/BPS Guide to Pharmacology CITE·2019· 2 citedOpen Access
VMAT2 Inhibitors and the Path to Ingrezza (Valbenazine)
Progress in medicinal chemistry·2018· 29 cited
Differences in Dihydrotetrabenazine Isomer Concentrations Following Administration of Tetrabenazine and Valbenazine
Drugs in R&D·2017· 32 citedOpen Access
Corticotropin-Releasing Factor Receptor 1 Antagonism Is Ineffective for Women With Posttraumatic Stress Disorder
Biological Psychiatry·2017· 92 citedOpen Access
Non-peptide CRF-Receptor Antagonists: Allosterism, Kinetics and Translation to Efficacy in Human Disease
Current Molecular Pharmacology·2017· 5 cited
664. Selectivity of Valbenazine (NBI-98854) and Its Major Metabolites on Presynaptic Monoamine Transport
Biological Psychiatry·2017
666. VMAT2 Inhibition: A Novel Mechanism for Maintained Efficacy at Lowered Antipsychotic Doses
Biological Psychiatry·2017
665. Valbenazine (NBI-98854) and Its Major Metabolites Specifically Modulate Neuronal Monoaminergic Function
Biological Psychiatry·2017
Pharmacologic Characteristics of Valbenazine (NBI-98854) and its Metabolites (P2.025)
Neurology·2017· 2 cited
Pharmacologic Characterization of Valbenazine (NBI-98854) and Its Metabolites
Journal of Pharmacology and Experimental Therapeutics·2017· 252 citedOpen Access
Corticotropin-Releasing Factor and Urocortin Receptors
Elsevier eBooks·2017
The CRF1 Antagonist Verucerfont in Anxious Alcohol-Dependent Women: Translation of Neuroendocrine, But not of Anti-Craving Effects
Neuropsychopharmacology·2016· 161 citedOpen Access
Single-Dose Study of a Corticotropin-Releasing Factor Receptor-1 Antagonist in Women With 21-Hydroxylase Deficiency
The Journal of Clinical Endocrinology & Metabolism·2016· 56 citedOpen Access
Hypocretin Receptor 2 Antagonism Dose-Dependently Reduces Escalated Heroin Self-Administration in Rats
Neuropsychopharmacology·2014· 79 citedOpen Access
page 1 of 9Next →

Frequent Co-authors

Errol B. De Souza(7), Philip Seeman(6), Timothy W. Lovenberg(5), Chen Liaw(5), Wylie Vale(5), Jean Rivier(4), Yvette Taché(4), Paul D. Crowe(4), Derek Chalmers(3), E B De Souza(3), Tallie Z. Baram(3), Richard A. Maki(3), Lixin Wang(3), Mulugeta Million(3), Patricia Shinnick‐Gallagher(3), Joel P. Gallagher(3), James R. McCarthy(3), Tilman Oltersdorf(2), Yuncai Chen(2), Céline Dubé(2)